FI119809B - NMDA-reseptorin 1-aminoalkyylisykloheksaaniantagonisteja - Google Patents

NMDA-reseptorin 1-aminoalkyylisykloheksaaniantagonisteja Download PDF

Info

Publication number
FI119809B
FI119809B FI992801A FI19992801A FI119809B FI 119809 B FI119809 B FI 119809B FI 992801 A FI992801 A FI 992801A FI 19992801 A FI19992801 A FI 19992801A FI 119809 B FI119809 B FI 119809B
Authority
FI
Finland
Prior art keywords
amino
ethyl
colors
compound
methyl
Prior art date
Application number
FI992801A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI19992801A (fi
Inventor
Ivars Kalvinsh
Wojciech Danysz
Markus Gold
Valerjans Kauss
Aigars Jirgensons
Christopher Graham Rap Parsons
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of FI19992801A publication Critical patent/FI19992801A/fi
Application granted granted Critical
Publication of FI119809B publication Critical patent/FI119809B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI992801A 1997-06-30 1999-12-29 NMDA-reseptorin 1-aminoalkyylisykloheksaaniantagonisteja FI119809B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88594497A 1997-06-30 1997-06-30
US88594497 1997-06-30
EP9804026 1998-06-24
PCT/EP1998/004026 WO1999001416A2 (en) 1997-06-30 1998-06-24 1-amino-alkylcyclohexane nmda receptor antagonists

Publications (2)

Publication Number Publication Date
FI19992801A FI19992801A (fi) 1999-12-29
FI119809B true FI119809B (fi) 2009-03-31

Family

ID=25388050

Family Applications (1)

Application Number Title Priority Date Filing Date
FI992801A FI119809B (fi) 1997-06-30 1999-12-29 NMDA-reseptorin 1-aminoalkyylisykloheksaaniantagonisteja

Country Status (26)

Country Link
US (1) US6034134A (no)
EP (1) EP1009732B1 (no)
JP (1) JP3963488B2 (no)
KR (1) KR100630506B1 (no)
CN (1) CN1136187C (no)
AR (1) AR010708A1 (no)
AT (1) ATE240936T1 (no)
AU (1) AU724974B2 (no)
CA (1) CA2292558C (no)
CZ (1) CZ293248B6 (no)
DE (1) DE69814878T2 (no)
DK (1) DK1009732T3 (no)
EA (1) EA002254B1 (no)
ES (1) ES2200358T3 (no)
FI (1) FI119809B (no)
GE (1) GEP20032995B (no)
HK (1) HK1029574A1 (no)
HU (1) HU226110B1 (no)
IL (1) IL133235A (no)
NO (1) NO314353B1 (no)
PL (1) PL193237B1 (no)
PT (1) PT1009732E (no)
TW (1) TW593225B (no)
UA (1) UA61962C2 (no)
WO (1) WO1999001416A2 (no)
ZA (1) ZA985678B (no)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2197319C (en) * 1994-08-29 2009-01-27 Louis S. Kucera Lipid analogs for treating viral infections
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
UA72558C2 (uk) * 1999-11-01 2005-03-15 Мерц Фарма Гмбх Унд Ко. Кгаа 1-аміноалкілциклогексанові антагоністи рецептора nmda
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
US6602862B1 (en) 2000-09-19 2003-08-05 Merz Pharma Gmbh & Co., Kgaa 1-Amino-alkylcyclohexanes as trypanocidal agents
CN1646141B (zh) 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
KR20030081343A (ko) * 2000-12-15 2003-10-17 파마셋, 리미티드 플라비비리다에 감염 치료용 항바이러스제
WO2002072542A2 (en) * 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
BR0307712A (pt) * 2002-02-14 2005-05-24 Pharmasset Ltd Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
MXPA04012709A (es) 2002-06-28 2005-09-30 Idenix Cayman Ltd Profarmacos modificados de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
TW200410672A (en) * 2002-07-19 2004-07-01 Merz Pharma Gmbh & Co Kgaa NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
MXPA05001298A (es) * 2002-08-01 2005-11-04 Pharmasset Inc Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae.
WO2004037234A2 (en) 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004046331A2 (en) 2002-11-15 2004-06-03 Idenix (Cayman) Limited 2’-branched nucleosides and flaviviridae mutation
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
WO2005003147A2 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
WO2005009421A2 (en) * 2003-07-28 2005-02-03 Merz Pharma Gmbh & Co. Kgaa The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
EP1682109B1 (en) * 2003-10-22 2008-10-15 Merz Pharma GmbH & Co. KGaA The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic as peptides in amyloidopathies
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
RS51540B (en) * 2004-01-05 2011-06-30 Merz Pharma Gmbh. & Co. Kgaa. MEMANTINE FOR THE TREATMENT OF Mild to Moderate Alzheimer's Disease
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
ES2483126T3 (es) 2004-06-17 2014-08-05 Merz Pharma Gmbh & Co. Kgaa Formulaciones de formas de dosificación de neramexano
JP2008503475A (ja) * 2004-06-17 2008-02-07 フォーレスト ラボラトリーズ, インコーポレイテッド メマンチンの放出が改変された製剤
WO2006000922A2 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP1809301B1 (en) 2004-09-14 2019-11-06 Gilead Pharmasset LLC 2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
TW200621677A (en) * 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
EP2007789B1 (en) 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
US8013018B2 (en) 2006-07-18 2011-09-06 Astellas Pharma Inc. Aminoindane derivative or salt thereof
BRPI0714622A2 (pt) 2006-08-04 2013-04-30 Merz Pharma Gmbh & Co Kgaa pirazolopirimidinas substituÍdas, processo para sua preparaÇço e seu uso como medicamento
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
EP2144604B1 (en) 2007-02-28 2011-09-21 Conatus Pharmaceuticals, Inc. Methods for the treatment of chronic viral hepatitis C using RO 113-0830
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
TW200916091A (en) * 2007-06-08 2009-04-16 Merz Pharma Gmbh & Amp Co Kgaa Neramexane for the treatment of nystagmus
KR20100045983A (ko) * 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 nmda 수용체 길항물질
EP2018854A1 (en) * 2007-07-27 2009-01-28 Merz Pharma GmbH & Co. KGaA Novel combinations of neramexane for the treatment of neurodegenerative disorders
RU2446794C2 (ru) * 2007-09-12 2012-04-10 Мерц Фарма Гмбх Унд Ко. Кгаа Терапия с интервалами для лечения тиннитуса
EP2548552B1 (en) * 2007-09-12 2015-11-18 Merz Pharma GmbH & Co. KGaA Titration package for 1-amino-alkylcyclohexanes
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2111858A1 (en) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Novel treatment for alzheimer's disease
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
ES2458358T3 (es) 2008-07-02 2014-05-05 Idenix Pharmaceuticals, Inc. Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2373304B1 (en) 2008-12-19 2014-07-30 Merz Pharma GmbH & Co. KGaA Neramexane for the treatment of mast cell mediated diseases
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP3222628A1 (en) 2008-12-23 2017-09-27 Gilead Pharmasset LLC Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8193372B2 (en) 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8784847B2 (en) * 2009-04-17 2014-07-22 Merz Pharma Gmbh & Co. Kgaa Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2448911A1 (en) 2009-06-29 2012-05-09 Merz Pharma GmbH & Co. KGaA Method of preparing 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane
WO2011000536A1 (en) 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Method of preparing 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane
JP5749261B2 (ja) * 2009-06-29 2015-07-15 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー 3,3,5,5−テトラメチルシクロヘキサノンを調製する方法
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
JP2013505902A (ja) * 2009-09-28 2013-02-21 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ネラメキサン又はその塩を調製する方法
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
PT3290428T (pt) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
WO2011123586A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US20110294890A1 (en) 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
EP2582356A1 (en) * 2010-06-18 2013-04-24 Merz Pharma GmbH & Co. KGaA Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
JP6084931B2 (ja) 2011-01-20 2017-02-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
WO2012107584A1 (en) 2011-02-11 2012-08-16 Universite Pierre Et Marie Curie (Paris 6) Methods for predicting outcome of a hepatitis virus infection
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
KR20140063657A (ko) 2011-08-03 2014-05-27 사이세리스 Hcv 면역요법
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
WO2013133927A1 (en) 2012-02-13 2013-09-12 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
EP2852603B1 (en) 2012-05-22 2021-05-12 Idenix Pharmaceuticals LLC D-amino acid compounds for liver disease
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
CN111848711A (zh) 2012-10-08 2020-10-30 埃迪尼克斯医药有限责任公司 用于hcv感染的2′-氯核苷类似物
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
JP2020505439A (ja) 2017-01-10 2020-02-20 オーウェン−バリー・ファーマシューティカルズ・インコーポレイテッドOwen−Barry Pharmaceuticals Inc. 抗痙攣薬化合物
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2023154014A1 (en) 2022-02-08 2023-08-17 Sahin Fikret Nmdar antagonists prevent ageing and aging-associated conditions and diseases through increasing 20s proteasome activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3541181A1 (de) * 1985-11-21 1987-05-27 Basf Ag Propylamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases

Also Published As

Publication number Publication date
JP2002511873A (ja) 2002-04-16
HU226110B1 (en) 2008-04-28
JP3963488B2 (ja) 2007-08-22
EP1009732A2 (en) 2000-06-21
EP1009732B1 (en) 2003-05-21
NO996548D0 (no) 1999-12-29
DE69814878D1 (de) 2003-06-26
KR100630506B1 (ko) 2006-09-29
NO314353B1 (no) 2003-03-10
NO996548L (no) 2000-02-28
IL133235A (en) 2004-02-19
HUP0100266A3 (en) 2003-07-28
CN1266423A (zh) 2000-09-13
FI19992801A (fi) 1999-12-29
CZ293248B6 (cs) 2004-03-17
WO1999001416A3 (en) 1999-08-19
DE69814878T2 (de) 2004-05-19
AU724974B2 (en) 2000-10-05
TW593225B (en) 2004-06-21
PT1009732E (pt) 2003-10-31
IL133235A0 (en) 2001-03-19
HUP0100266A2 (hu) 2002-05-29
ZA985678B (en) 2000-01-10
ATE240936T1 (de) 2003-06-15
AR010708A1 (es) 2000-07-12
PL337809A1 (en) 2000-09-11
HK1029574A1 (en) 2001-04-06
WO1999001416A2 (en) 1999-01-14
CA2292558C (en) 2006-09-19
ES2200358T3 (es) 2004-03-01
EA002254B1 (ru) 2002-02-28
AU8804298A (en) 1999-01-25
PL193237B1 (pl) 2007-01-31
CZ457199A3 (cs) 2000-06-14
US6034134A (en) 2000-03-07
EA200000080A1 (ru) 2000-08-28
CN1136187C (zh) 2004-01-28
UA61962C2 (uk) 2003-12-15
KR20010013738A (ko) 2001-02-26
CA2292558A1 (en) 1999-01-14
DK1009732T3 (da) 2003-09-22
GEP20032995B (en) 2003-06-25

Similar Documents

Publication Publication Date Title
FI119809B (fi) NMDA-reseptorin 1-aminoalkyylisykloheksaaniantagonisteja
US6071966A (en) 1-amino-alkylcyclohexane NMDA receptor antagonists
KR100412154B1 (ko) N-프로파길-1-아미노인단의r-에난시오머,염,및그들의조성물의사용
DE69218101T2 (de) Monofluorierte Derivate von N-Propargyl-1-Aminoindan und deren Verwendung als Monoamino-Oxidaseinhibitoren
EP1542961B1 (en) Trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine for use in treatment of cns disorders
JP6328170B2 (ja) 治療化合物
JP2003160481A (ja) N−プロパルギル−1−アミノインダン、これらの塩、組成物、及びこれらの使用
US20100298442A1 (en) 1-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
US6828462B2 (en) Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US20060019982A1 (en) Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists
AU2002337389A1 (en) Unsaturated 1-amino-alkylcyclohexane NMDA,5HT3 and neuronal nicotinic receptor antagonists
US20230022767A1 (en) Salts of (2r, 6r)-hydroxynorketamine, their crystal forms, and methods of making the same
MXPA99011993A (en) 1-amino-alkylcyclohexane nmda receptor antagonists
ZA200403456B (en) Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists.
TW200407120A (en) Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119809

Country of ref document: FI

MM Patent lapsed